Not using Bio­strength for BE [Regulatives / Guidelines]

posted by zheng791 – US, 2018-07-13 21:31 (1537 d 10:30 ago) – Posting: # 19052
Views: 2,608

Our firm is developing a multi-strength product which is a high potency, NTI oral dosage. The highest strength is 0.3 mg. The product guidance requests to use 0.3 mg x2 tablets for dosing and biowaive the lower strengths. However, our firm does not want to develop 0.3 mg. They have 0.15 mg as highest strength. Can I use 0.15 mg x4 for dosing and biowaive lower strengths? These strengths are similarly proportional, that is have the same tablet weight, the filler weight changes to compensate the API change.

Thank you

Complete thread:

UA Flag
 Admin contact
22,391 posts in 4,685 threads, 1,595 registered users;
online 5 (0 registered, 5 guests [including 4 identified bots]).
Forum time: Wednesday 08:02 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz